Physician profile
Amjad Farooq
NPI 1366447377
$1,382.42
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.96 · 2020: $171 · 2021: $274 · 2022: $420 · 2023: $413 · 2024: $31.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $154.57 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.49 | 2019-2022 | |
| Amgen INC. | $99.83 | 2020-2023 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $94.39 | 2019-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $92.86 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $76.80 | 2020-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $75.09 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $70.42 | 2022 | |
| Dexcom, INC. | $60.46 | 2021-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $60.43 | 2022-2023 | |
| Novo Nordisk INC | $59.08 | 2020-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $50.13 | 2022 | |
| Horizon Therapeutics Plc | $40.86 | 2021-2022 | |
| Pfizer INC. | $37.33 | 2021-2023 | |
| Shield Therapeutics INC | $33.23 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $32.61 | 2019 | |
| Merck Sharp & Dohme LLC | $32.12 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $30.09 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.37 | 2022-2023 | Eliquis |
| Amarin Pharma, INC. | $28.93 | 2021 | |
| Astellas Pharma US INC | $27.20 | 2021 | |
| Exact Sciences Corporation | $20.64 | 2023 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $17.43 | 2023 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $16.07 | 2024 | |
| Medtronic USA, INC. | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.